Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Equillium, Inc.

Get SEC filing alerts via email and in your feed for Equillium, Inc.

EQ

Equillium, Inc.

About Equillium, Inc.

Equillium, Inc. is a biotechnology company focused on developing novel immuno-inflammatory therapeutics. Its pipeline includes first-in-class monoclonal antibodies and multi-cytokine inhibitors targeting severe autoimmune and inflammatory diseases such as graft-versus-host disease, celiac disease, and alopecia areata. The company leverages proprietary platforms and strategic partnerships to advance clinical candidates and aims to commercialize therapies that address high unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Equillium, Inc.

1
1
Equillium, Inc. Equillium Reports Q1 2026 Financial Results with $5.3M Net Loss and Increased Cash Reserves

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Equillium, Inc. Equillium Reports No Revenue and Increased Net Loss in 2025 Financial Filing

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Equillium, Inc. Equillium Reports Zero Revenue and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Equillium, Inc. Equillium Reports Zero Revenue and $5.7 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Equillium, Inc. Equillium Reports No Revenue and Increased Losses in Latest Financial Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Equillium, Inc. Equillium Reports $8.1 Million Net Loss and $41.1 Million Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Equillium, Inc. Equillium Reports Revenue Growth, Improved Net Loss, and Strategic Focus on Lead Product Candidate

Via official filing (AI summary) | over 1 year ago | 0 comments